#LRMR

Larimar Therapeutics Reports Third Quarter 2025 Financial Results Larimar Therapeutics (Nasdaq: LRMR) reported Q3 2025 results and program updates for nomlabofusp for Friedreich’s ataxia. Key clinical highlights include 100% of 10 participants achieving skin frataxin (FXN) >50% of healthy median at 6 months and a median mFARS improvement of 2.25 at 1 year versus a median worsening of 1.00 in a FACOMS reference population. Larimar plans a BLA seeking accelerated approval in Q2 2026 and targets U.S. launch in early 2027. Financially, Larimar reported $175.4M cash as of Sept 30, 2025, with runway into Q4 2026.

4 months ago

#LRMR Larimar Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Investors of Larimar Therapeutics Under Scrutiny for Possible Fraud Violations A significant investigation is underway into Larimar Therapeutics, Inc., following allegations of misleading statements affecting shareholders. Learn more about the situation.

Investors of Larimar Therapeutics Under Scrutiny for Possible Fraud Violations #USA #Los_Angeles #Schall_Law_Firm #Larimar_Therapeutics #LRMR

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Most Searched, Monday September 29, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Sept 29th - #EOSE #KALA #RZLV #RXRX #DWTX #HIVE #RR #BQ #LRMR #RIG #BYND #ONDS #PLUG #BBAI #DNN #TLRY #LUNR #LAC #NEOG - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Monday September 29, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading Mon Sept 29th - #YAAS #MTEK #JZXN #QSI #LRMR #KALA #IOBT #CLLS #BYND - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia Larimar Therapeutics (NASDAQ:LRMR) reported positive data from its ongoing long-term open label study of nomlabofusp for Friedreich's ataxia (FA). The study showed that all 10 participants with 6-month data achieved skin frataxin (FXN) levels over 50% of median levels found in healthy volunteers, comparable to levels in asymptomatic carriers.Key highlights include consistent improvements across 4 clinical outcomes after 1 year of treatment compared to natural history data, with 39 participants receiving at least one dose and 25 currently on daily dosing. However, 7 participants experienced anaphylaxis within the first 6 weeks of dosing, leading to protocol modifications. The company plans to submit a BLA for accelerated approval in Q2 2026.

5 months ago

#LRMR Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

5 months ago

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Avalo Therapeutics (NASDAQ:AVTX) Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS ) rose sharply in today's pre-market trading . Genmab announced plans to acquire...

#AVTX #BIAF #CGC #CLLS #CYCU #ENTA #ENTA #EPOW #JFB #LRMR #MLTX

Origin | Interest | Match

0 0 0 0

InsiderFinance

@insiderfinance.com

5 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IFRX 96% OTM
2. #RZLV 67% OTM
3. #LRMR 61% OTM
4. #TSLA 53% OTM
5. #UPST 53% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

5 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #BITF 79% OTM
2. #LRMR 61% OTM
3. #GME 46% OTM
4. #WOLF 43% OTM
5. #SOFI 40% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

5 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BITF, #LRMR, #WOLF, #SOFI, #DAL

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Larimar's Friedreich's Ataxia Drug Nears BLA Filing as FDA Provides Clear Path Forward Biotech firm reports key milestones for nomlabofusp in Friedreich's ataxia treatment, with FDA backing surrogate endpoint approach. Critical data expected September 2025. Learn more.

7 months ago

#LRMR Larimar Therapeutics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Larimar Therapeutics Announces Pricing of Underwritten Public Offering Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotech company, has announced the pricing of its underwritten public offering of 18.75 million shares of common stock at $3.20 per share. The offering is expected to generate $60 million in gross proceeds before deducting expenses.The company has granted underwriters a 30-day option to purchase up to an additional 2.81 million shares. The offering, expected to close around July 31, 2025, is being managed by Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair. Proceeds will support the development of nomlabofusp, other pipeline candidates, and general corporate purposes including R&D and pre-commercialization expenses.

7 months ago

#LRMR Larimar Therapeutics Announces Pricing of Underwritten Public Offering

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Rare Disease Biotech Larimar Therapeutics Unveils Strategic Public Offering for Breakthrough Drug Development Clinical-stage biotech initiates funding round to accelerate nomlabofusp development and expand rare disease pipeline. Learn about investment terms.

7 months ago

#LRMR Larimar Therapeutics Announces Proposed Underwritten Public Offering

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval New data supports nomlabofusp as first potential disease-modifying therapy for Friedreich's ataxia. BLA submission planned for Q2 2026. See breakthrough findings.

8 months ago

#LRMR Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program Larimar Therapeutics (LRMR) has received FDA recommendations for its nomlabofusp Biologics License Application (BLA) for treating Friedreich's Ataxia. The FDA recommends a safety database of at least 30 participants with 6-month continuous exposure and 10 participants with 1-year exposure, primarily at the 50 mg dose. The company plans to submit its BLA in Q2 2026, seeking accelerated approval. The FDA is open to using skin frataxin concentrations as a reasonably likely surrogate endpoint. Larimar expects to report data from 30-40 participants in their open-label extension study and adolescent PK run-in data in September 2025. The company is advancing its global Phase 3 study with sites in multiple countries, which will serve as the confirmatory study for accelerated approval.

8 months ago

#LRMR Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Crucial FDA Update Coming: Larimar's Breakthrough Friedreich's Ataxia Drug Faces Regulatory Milestone Larimar reveals regulatory progress for nomlabofusp in rare disease treatment. Join crucial update call for latest development status in Friedreich's Ataxia program. Get insights.

8 months ago

#LRMR Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge FDA signals openness to fast-track approval for Larimar's nomlabofusp treatment. Q1 results show $157.5M cash position. Phase 3 trial ahead. Get full details.

10 months ago

#LRMR Larimar Therapeutics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment FDA considers surrogate endpoint for nomlabofusp in Friedreich's ataxia treatment. Phase 3 study planned for mid-2025 with $183.5M cash runway. Full analysis inside.

11 months ago

#LRMR Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Larimar Therapeutics Begins Pediatric Dosing of Nomlabofusp for Friedreich's Ataxia Treatment Larimar initiates adolescent trial phase for nomlabofusp, targeting Friedreich's ataxia patients aged 12-17. Study participants to receive weight-based doses over 7-day period.

1 year ago

#LRMR Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

Larimar's Nomlabofusp Shows Breakthrough Results in Friedreich's Ataxia Treatment, FXN Levels Surge 72% Larimar Therapeutics reports promising clinical data for Friedreich's Ataxia drug nomlabofusp, with significant FXN increases and positive patient outcomes in extension study.

1 year ago

#LRMR Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

1 year ago

#LRMR Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

www.stocktitan.net/news/LRMR/larimar-therap...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #LRMR ) Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

#StockMarket #News

1 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #LRMR ) LRMR Price Target Alert: $22.00. Issued by Wedbush

#StockMarket #News

1 0 0 0

1 year ago

News; ( NASDAQ: #LRMR ) Outperform Recommendation Issued On LRMR By Wedbush

#StockMarket #News

1 0 0 0